Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Hikma Pharmaceutical (HKMPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,082,294
  • Shares Outstanding, K 240,867
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 0.45
  • Price/Sales 2.57
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.1000 unch
on 03/18/19
22.1000 -4.52%
on 02/19/19
-1.4000 (-6.22%)
since 02/14/19
3-Month
19.8000 +6.57%
on 01/17/19
22.7500 -7.25%
on 12/20/18
-2.9000 (-12.08%)
since 11/09/18
52-Week
14.0000 +50.71%
on 07/24/18
26.3964 -20.06%
on 11/08/18
+5.6000 (+36.13%)
since 03/16/18

Most Recent Stories

More News
Hikma Pharmaceuticals Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Hikma Pharmaceuticals Plc (OTC PINK: ) will be discussing their earnings results in their 2018 Second Half Earnings to be held on March 12, 2019, 2018 at 9:30...

HKMPF : 21.1000 (-4.52%)
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

IRWD : 14.11 (+3.07%)
AGN : 153.53 (-0.09%)
HKMPF : 21.1000 (-4.52%)
IONS : 80.50 (+0.36%)
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

CPIX : 5.90 (+0.68%)
HKMPF : 21.1000 (-4.52%)
BSTC : 67.78 (-0.21%)
OCUL : 4.16 (unch)
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.

JNJ : 138.10 (+0.59%)
HKMPF : 21.1000 (-4.52%)
KPTI : 5.82 (+7.78%)
BSTC : 67.78 (-0.21%)
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

NBIX : 89.83 (+5.89%)
HKMPF : 21.1000 (-4.52%)
ABBV : 81.24 (+1.01%)
BSTC : 67.78 (-0.21%)
Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study

Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.

SPPI : 10.21 (+2.00%)
HKMPF : 21.1000 (-4.52%)
AMGN : 191.89 (+0.40%)
BSTC : 67.78 (-0.21%)
Flexion Starts Phase III Enrollment on Zilretta for Hip OA

Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.

CPIX : 5.90 (+0.68%)
HKMPF : 21.1000 (-4.52%)
FLXN : 12.54 (+4.59%)
BSTC : 67.78 (-0.21%)
UPDATE - Hikma Pharmaceutical Plants Sold to Investor Group

A joint venture between Gordon Brothers and New Mill Capital Holdings has acquired three buildings from Hikma Pharmaceuticals in the Eatontown Industrial Park in Eatontown, NJ. The transaction closed on...

HKMPF : 21.1000 (-4.52%)
Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis

Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.

SPPI : 10.21 (+2.00%)
HKMPF : 21.1000 (-4.52%)
AMGN : 191.89 (+0.40%)
BSTC : 67.78 (-0.21%)
Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

MDWD : 5.17 (-1.34%)
ESALY : 52.6000 (-35.01%)
CPIX : 5.90 (+0.68%)
HKMPF : 21.1000 (-4.52%)
ORINY : 17.2200 (+1.59%)
BSTC : 67.78 (-0.21%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade HKMPF with:

Key Turning Points

2nd Resistance Point 21.1000
1st Resistance Point 21.1000
Last Price 21.1000
1st Support Level 21.1000
2nd Support Level 21.1000

See More

52-Week High 26.3964
Fibonacci 61.8% 21.6610
Last Price 21.1000
Fibonacci 50% 20.1982
Fibonacci 38.2% 18.7354
52-Week Low 14.0000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar